

No.	Date Received	Clinical Trial Registration Number	Name of the Trial	Name of the PI	Phase	Sponsor	Investigational Product	Status
1	20/1/2025	CTM/045/2025	Can a higher dose overcome clopidogrel resistance - a study of 150 mg daily, in patients with normal platelet function with and without cyp2c19 gene polymorphism.	Dr.Ruvan A.I.Ekanayaka	3	Non-commercial	Clopidogrel	Application evaluation process closed due to non-response from the applicant
2	27/1/2025	CTM/046/2025	AEFIX Trial: A Multicenter Randomized Controlled Trial Assessing Safety and Efficacy of a Novel, Affordable Fracture External	Dr.S. Gobishangar	3	Non-commercial	Fracture External Fixation system	Not come under NMRA purview
3	29/1/2025	CTM/047/2025	Effectiveness of magnesium sulphate as an adjuvant therapy compared to standard treatment in patients with acute oleander poisoning in selected hospitals, Sri Lanka : A double blind randomized controlled trial	Dr.W.M.A.B.W. Eriyawa	3	Non-commercial	Magnesium Sulphate	Approved 25/05/2025
4	3/2/2025	CTM/048/2025	A multicenter open-labelled randomized controlled trial to evaluate the effect of moderate-dose and high-dose intravenous methylprednisolone combined with plasmapheresis versus plasmapheresis alone in Leptospirosis pulmonary haemorrhage syndrome	Dr.Nilanka Perera	3	Non-commercial	Methylprednisolone combined with plasmapheresis	Approved 10/10/2025

5	6/2/2025	CTM/049/2025	Efficacy of different regimens of oral iron therapy in treatment of iron deficiency anaemia; A randomized	Prof.K. Chamila D. Mettananda	3	Non-commercial	Oral iron	Approved 13/06/2025
6	11/2/2025	CTM/050/2025	A randomized, double-blind, placebo-controlled pragmatic study to evaluate Finerenone on clinical efficacy and safety in patients with Heart Failure and reduced ejection fraction who are intolerant of or not eligible for treatment with steroidal mineralocorticoid receptor antagonists (FINALITY-HF)	Dr.Gamini Galappatthy	3	CPC Clinical Research, USA	Finerenone	Approved 22/08/2025
7	10/3/2025	CTM/051/2025	The Chronic Kidney disease Adaptive platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE)	Dr.Selvarajah Mathu	3	The George Institute for Global Health, Australia	Finerenone	Approved 13/06/2025
8	10/3/2025	CTM/052/2025	A phase III, 52-week, Prospective, Randomized, double-blind, Placebo controlled, parallel-Group, Multi-Center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15mg bid and 30mg bid of Evenamide as add-on in patients with documented Treatment-Resistant Schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient's current antipsychotic	Prof. Shehan Williams	3	Newron Pharmaceuti cals S.P.A., Italy	Evenamide	Approved 22/08/2025

9	8/5/2025	CTM/053/2025	A Phase 111 Randomized controlled clinical trial to compare the efficacy and safety of intra-lesional sodium stibogluconate and intra-lesional meglumine antimoniate treatment in patients with cutaneous leishmaniasis in Sri Lanka	Prof. Shalindra Ranasinghe	3	Non-commercial	Meglumine Antimoniate	Approved 30/10/2025
10	16/5/2025 (Revised version of the initial protocol submitted on 14/02/2023)	CTM/032/2023	A randomized controlled, open-label study to evaluate the safety and efficacy of antivenom serum Sri Lanka (SL-AVS) vs currently used Indian anti-venom serum (Indian- AVS) against big four snakes in Sri Lanka and to estimate the optimal dose for hump-nosed viper bite patients.	Prof. S.A.M. Kularathne	2 & 3	Premium serums and vaccines Pvt. Ltd., India	Snake venom antiserum Sri Lanka	Approved 12/12/2025
11	30/6/2025	CTM/054/2025	A multi- factorial, multi-arm, multi-stage, randomized, global adaptive platform trial for stroke (ACT-GLOBAL)	Dr. Harsha Gunasekare	3	The George Institute for Global Health, Australia	Colchicine and Deferoxamine mesylate	Approved 10/10/2025
12	11/7/2025	CTM/055/2025	Effectiveness of combining letrozole with misoprostol compared to misoprostol alone in the medical management of missed miscarriage -	Prof. Rasika Herath	3	Non-commercial	Letrozole with Misoprostol	Approved 14/11/2025
13	29/10/2025	CTM/056/2025	Comparing the efficacy of Platelet-Rich Plasma Versus Methylprednisolone in the Management of Oral Submucous Fibrosis Patients at National Hospital,	Dr. D.K. Dias	3	Non-commercial	Platelet-Rich Plasma	Not come under NMRA purview

14	10/12/2025	CTM/057/2025	A double-blind randomized controlled trial of the feasibility and acceptability of folic acid supplementation in reducing depression and suicidal behaviour: A pilot study	Prof. Dewasmika Indrapali Ariyasinghe, Prof. Thilini Rajapakse	3	Non-commercial	Folic acid	Awaiting responses of the applicant to review comments
----	------------	--------------	--	--	---	----------------	------------	--